1 Min Read
STOCKHOLM, Jan 4 (Reuters) - Sobi
* Says Health Canada Approves Orfadin Capsules for Treatment of Hereditary Tyrosinaemia Type-1 (HT-1)
Source text for Eikon:
Further company coverage: (Reporting by Stockholm Newsroom)
All quotes delayed a minimum of 15 minutes. See here for a complete list of exchanges and delays.
© 2017 Reuters. All Rights Reserved.